Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
doxorubicin + gemcitabine
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Doxorubicin + gemcitabine is a combination chemotherapy regimen consisting of two cytotoxic agents, doxorubicin and gemcitabine. Doxorubicin is an anthracycline antibiotic that intercalates DNA, inhibits topoisomerase II, and generates free radicals leading to DNA damage and apoptosis. Gemcitabine is a nucleoside analog that inhibits DNA synthesis by incorporating into DNA during replication, causing chain termination and cell cycle arrest. This combination has been studied primarily in advanced or metastatic breast cancer as well as other solid tumors. The regimen aims to leverage the complementary mechanisms of action for enhanced antitumor activity while maintaining manageable toxicity profiles[1][2]. Both drugs are administered intravenously.
- Other names
- Gemzar + Doxil
02
Targets
TOP2A (DNA topoisomerase II)DNA polymerase family
Beyond the preview
Go deeper on doxorubicin + gemcitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on doxorubicin + gemcitabine.